[Anticoagulants and thrombocyte aggregation inhibitors in or following myocardial infarct].
D000925:Anticoagulants / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004176:Dipyridamole / Q000627:therapeutic use; D004311:Double-Blind Method; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D009203:Myocardial Infarction / Q000097:blood / Q000188:drug therapy*; D010974:Platelet Aggregation / Q000187:drug effects*; D012008:Recurrence; D013442:Sulfinpyrazone / Q000627:therapeutic use
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D004176:Dipyridamole; D001241:Aspirin; D013442:Sulfinpyrazone
Antikoagulantien und Thrombozytenaggregationshemmer bei/nach Myokardinfarkt.